Revolax Sub-Q with Lidocaine effectively addresses deep to very deep facial wrinkles and skillfully contours different facial areas for a natural appearance
Revolax Sub-Q, a cutting-edge filler, addresses deep to extremely deep facial wrinkles by replenishing lost volume in the face, rectifying asymmetrical facial features, and smoothing very deep nasolabial folds. This versatile filler is also employed to enhance and balance the nose, jawline, chin, and cheeks. Specifically, it can straighten the nasal bridge and refine the nasal tip according to desired specifications.
Understanding the Functionality of Revolax Sub-Q
Revolax Sub-Q is primarily designed to address deep to extremely deep wrinkles, effectively smoothing and diminishing persistent nasolabial folds and smile lines over time. Its hyaluronic acid content delivers sustained moisture to the skin and underlying tissues, enhancing firmness. Formulated as a gel with a high concentration of cross-linked hyaluronic acid, Revolax Sub-Q with lidocaine is both biologically sourced and non-animal derived, exhibiting a viscous consistency. This characteristic allows for exceptionally enduring outcomes, promoting a rejuvenated and refreshed complexion in the long run.
What Distinguishes the Revolax Range
Introduced in 2012, the Revolax line of dermal fillers has consistently provided exceptionally safe, low-risk, and user-friendly application methods, delivering top-notch, enduring outcomes. This success is largely due to its innovative technology, positioning Revolax as a prominent and widely favored choice among dermal fillers in South Korea and Asia. This achievement is enabled by the high concentration of non-animal hyaluronic acid, which seamlessly aligns with human skin tissue.
Product Composition and Treatment Guidelines of Revolax Sub-Q with Lidocaine
A package of Revolax Sub-Q contains an injection syringe with a volume of 1.1 ml. The filler is composed of cross-linked hyaluronic acid with a concentration of 24 mg/ml. Alongside hyaluronic acid, it includes 3 mg/ml of lidocaine. The filler has the capability to be injected either into the mid to deep dermis or into the subcutaneous layer. Following treatment, the effects of this filler typically become apparent right away. However, the timeframe may differ based on the patient's skin condition. Additionally, swelling might occur post-treatment, which needs to diminish before the results become visible. The effectiveness of this product typically lasts up to 12 months following treatment, varying based on the patient's skin type and individual factors. Several aspects influence the duration and intensity of the effect, such as the customer's age, skin type, and level of physical activity. Furthermore, the technique used to apply the filler also plays a significant role. As a result, the patient may require additional or fewer treatments accordingly.
Distribution is permissible solely upon presentation of a valid medical prescription. This directive does not pertain to individuals engaged in the field of healing or healthcare.
Both the manufacturer and we, in our capacity as the vendor, stress the importance of injections involving products containing or lacking lidocaine being administered solely by proficient and medically qualified personnel.
